Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Positron Emission Tomography Guided Therapy of Aggressive Non-Hodgkin's Lymphomas

Next Previous
X
Search
Trial Profile

Positron Emission Tomography Guided Therapy of Aggressive Non-Hodgkin's Lymphomas

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 28 Jan 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Carmustine (Primary) ; Cisplatin (Primary) ; Cyclophosphamide (Primary) ; Cytarabine (Primary) ; Dexamethasone (Primary) ; Doxorubicin (Primary) ; Etoposide (Primary) ; Filgrastim (Primary) ; Ifosfamide (Primary) ; Melphalan (Primary) ; Methotrexate (Primary) ; Methylprednisolone (Primary) ; Pegfilgrastim (Primary) ; Prednisone (Primary) ; Rituximab (Primary) ; Stem cell therapies (Primary) ; Vincristine (Primary) ; Vindesine (Primary)
  • Indications Non-Hodgkin's lymphoma
  • Focus Therapeutic Use
  • Acronyms PETAL

    • Most Recent Events

    • 14 Dec 2021 Results (N 323) HOVON-84, HOVON-130, and PETAL trials investigating ability to predict outcome in DLBCL can be improved by combining different clinical, radiomics and genetic features presented at the 63rd American Society of Hematology Annual Meeting and Exposition
    • 08 Dec 2020 Results (N=2306), of pooled analysis of data from Petal, GOYA and real world to validate the tool for identification of ultra-high risk DLBCL patients1presented at the 62nd Annual Meeting and Exposition of the American Society of Hematology
    • 04 Feb 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top